Group 1 - The article discusses the recent changes in the U.S. tariff policy regarding pharmaceuticals, stating that the new tariffs will not apply to countries that have trade agreements with the U.S. [3][4] - On September 26, U.S. pharmaceutical stocks showed mixed performance, with Novavax rising by 2.52% and Pfizer increasing by 0.68%, while Moderna and UnitedHealth saw declines of 0.49% and 0.43%, respectively [3]. - The U.S. will impose a 100% tariff on imported brand-name or patented drugs starting October 1, unless companies establish manufacturing facilities in the U.S. [6]. Group 2 - The White House confirmed that the new tariffs on pharmaceuticals will adhere to existing agreements, maintaining a 15% tariff cap for the EU and Japan [4]. - British officials indicated that the UK is willing to negotiate higher prices for certain pharmaceuticals to protect exports to the U.S. [5]. - The Canadian steel industry has faced significant declines in production and exports due to U.S. tariffs, with a 24.8% drop in output since March and a 25.5% decrease in exports of non-alloy steel by July [7][8].

Group 1: Core Views - The recent U.S. tariff policy changes will not apply to countries that have trade agreements with the U.S., such as the EU and Japan, which will maintain a 15% tariff cap on pharmaceuticals [2][4] - President Trump announced a 100% tariff on all brand-name and patented drugs starting October 1, 2025, unless companies establish manufacturing in the U.S. [4][5] - The U.S. Chamber of Commerce has urged the government to reconsider new tariffs on heavy trucks, emphasizing that major import sources are allies and do not pose a security threat [6] Group 2: Market Reactions - Following the announcement of the new tariffs, pharmaceutical stocks showed mixed performance in the U.S. market, with Novavax rising by 2.52% and Moderna falling by 0.49% [1] - Japanese and South Korean pharmaceutical stocks mostly declined, with notable drops including Sumitomo Pharma down over 3% and Samsung Biologics down over 2% [1] Group 3: Impact on Other Industries - The Canadian steel industry has faced significant declines due to U.S. tariffs, with production down 24.8% and exports down 25.5% since March [7] - The U.S. Labor Statistics Bureau reported a 4.7% year-over-year increase in furniture prices due to tariff impacts [5]

Group 1 - The presentation focuses on Moderna's oncology portfolio, which has not been a primary focus in the company's narrative over the past 5 to 10 years [2] - The session will include a presentation followed by a Q&A segment, encouraging audience participation through the Pigeonhole app for questions [3] - Courtney Breen from Sanford C. Bernstein & Co. is leading the discussion, highlighting the importance of understanding the context of Moderna's oncology business [1][2] Group 2 - Rose Loughlin from Moderna is expected to provide insights during the presentation, indicating a collaborative effort to enhance understanding of the company's oncology initiatives [3]

Summary of the Conference Call Company and Industry - **Company**: Moderna - **Industry**: Oncology and mRNA-based therapeutics Key Points and Arguments 1. **Oncology Portfolio Overview**: Moderna is advancing a diverse oncology portfolio utilizing multiple therapeutic approaches and platform technologies to address various cancer types and stages [5][27] 2. **Individualized Neoantigen Therapy (INT)**: INT is a personalized therapy that identifies patient-specific neoantigens from tumor samples, showing promising results in combination with Keytruda, reducing recurrence risk by 49% and distant metastasis risk by 62% [6][7] 3. **Phase Three Study**: A phase three study in adjuvant melanoma combining INT with Keytruda has completed enrollment, with data expected in 2026 [9] 4. **Expansion of INT Development**: INT is being tested across multiple tumor types, including non-small cell lung cancer and bladder cancer, with various combinations [10] 5. **Off-the-Shelf Cancer Antigen Therapies**: Moderna is developing off-the-shelf therapies like mRNA-4359, which targets shared antigens in cancer cells, aiming for broader applicability across different cancer types [11][12] 6. **T Cell Engagers**: The company is developing T cell engagers that guide immune responses towards cancer cells, addressing tumor heterogeneity and immune dysfunction in advanced cancers [18][19] 7. **Cell Therapy Enhancers**: Moderna is exploring in vivo cell therapies to enhance the efficacy of existing CAR-T therapies, potentially improving outcomes in solid tumors [25][26] 8. **Partnerships**: Moderna has a 50/50 partnership with Merck for INT and collaborates with Immatics for T cell receptor development, leveraging external expertise to enhance their capabilities [60][61] 9. **Future Catalysts**: Key upcoming data releases include the five-year follow-up for INT in 2026 and additional data from ongoing studies in various cancer types [39][40] 10. **Competitive Landscape**: Moderna is monitoring competitors like BioNTech and IO Biotech, assessing their data to inform and de-risk its own development strategies [51][52] Other Important Content 1. **Safety and Tolerability**: The safety profiles of INT and other therapies are encouraging, with low-grade adverse events reported [7][14] 2. **Translational Data Importance**: Translational data from early studies will guide future development and inform the potential clinical benefits of therapies [64] 3. **Diverse Therapeutic Approaches**: Moderna's strategy involves a toolkit approach, tailoring therapies based on cancer stage and patient needs, from preventive to advanced settings [30][31] 4. **Market Opportunities**: The company sees potential in both solid and liquid tumors, with a focus on enhancing immune responses in challenging environments [36][44] 5. **Long-term Vision**: Moderna aims to significantly impact patient lives through its diverse oncology portfolio, leveraging its mRNA platform technology [67]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

mRNA-4157/V940 in combination with KEYTRUDA - At ~3 years of follow-up, the recurrence-free survival rate of mRNA-4157/V940 in combination with KEYTRUDA was 74.8%, compared to 55.6% for KEYTRUDA alone[12] - At a median planned follow-up of 34.9 months, mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 49%[14] - At ~3 years of follow-up, mRNA-4157/V940 in combination with KEYTRUDA demonstrated a 62% reduction in the risk of developing distant metastasis or death compared to KEYTRUDA alone[17] Safety and Tolerability of mRNA-4157/V940 - In the adjuvant melanoma trial, any treatment-related adverse event occurred in 100% of patients (n=104) receiving mRNA-4157 (V940) + pembrolizumab, with Grade ≥ 3 events in 25% of patients[18] - Serious adverse events occurred in 14.4% of patients (n=15) receiving mRNA-4157 (V940) + pembrolizumab[18] - Immune-related adverse events occurred in 37.5% of patients (n=39) receiving mRNA-4157 (V940) + pembrolizumab, with Grade ≥ 3 events in 10.6% of patients[18] - 94.2% of patients (n=98) experienced mRNA-4157 (V940)-related adverse events, with 33.7% Grade 1, 49% Grade 2, and 11.5% Grade 3[18] Development Programs - The Phase 3 study for adjuvant melanoma with mRNA-4157/V940 is fully enrolled[21, 22] - mRNA-4359 is ongoing in Phase 1/2 study; now enrolling Phase 2 with additional indications planned[27] - mRNA-2808 is in Phase 1 development[41] - mRNA-4203: IND open, in combination with Immatics' IMA203[49]

Core Insights - The Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire is now fully operational, licensed to supply British-made COVID-19 vaccines to the UK population [1] - This facility is a key component of Moderna's ten-year strategic partnership with the UK Government, aimed at enhancing health resilience and promoting economic growth [1] - The MITC will produce mRNA respiratory vaccines for the UK public, supporting the National Health Service (NHS) seasonal vaccination programs [1]

Group 1 - The analyst had a sell call on Moderna (MRNA) in April 2025, which was considered bold at the time due to the significant correction and perception of limited further downside [1] - The analyst has over 20 years of experience in quantitative research, financial modeling, and risk management, focusing on equity valuation, market trends, and portfolio optimization [1] - The analyst previously served as Vice President at Barclays, leading teams in model validation, stress testing, and regulatory finance, indicating a strong background in both fundamental and technical analysis [1] Group 2 - The analyst collaborates with a research partner, who is also their spouse, to co-author investment research, combining complementary strengths for high-quality insights [1] - The research approach emphasizes rigorous risk management and a long-term perspective on value creation, with a focus on macroeconomic trends, corporate earnings, and financial statement analysis [1] - The goal is to provide actionable ideas for investors aiming to outperform the market [1]

Core Insights - Moderna's updated COVID-19 vaccine formulation has shown a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying health condition [1] Company Summary - The company has focused on enhancing its vaccine formulation to improve immune responses among older adults and those with underlying health issues [1]

Core Insights - Moderna announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 [1] - The vaccine demonstrated a greater than 16-fold increase in LP.8.1-neutralizing antibodies across age groups [1] Company Summary - The ongoing Phase 4 clinical trial evaluates the safety, tolerability, and immunogenicity of the 2025-2026 formula of mNEXSPIKE [1] - The vaccine showed strong immune responses against the top circulating COVID-19 strains [1] Age Group Analysis - The data indicates a significant increase in neutralizing antibodies in individuals aged 12 to 64 with underlying conditions and all adults aged 65 and older [1]